open access

Vol 69, No 3 (2018)
Original papers
Published online: 2018-05-08
Submitted: 2017-10-20
Accepted: 2017-12-22
Get Citation

Study on the relationship between the methylation of the MMP-9 gene promoter region and diabetic nephropathy

Xiao-Hui Yang, Shi-Ya Feng, Yang Yu, Zhou Liang
DOI: 10.5603/EP.a2018.0029
·
Pubmed: 29952417
·
Endokrynologia Polska 2018;69(3):269-275.

open access

Vol 69, No 3 (2018)
Original papers
Published online: 2018-05-08
Submitted: 2017-10-20
Accepted: 2017-12-22

Abstract

Objective: This study aims to explore the relationship between the methylation of matrix metalloproteinase (MMP)-9 gene promoter region and diabetic nephropathy (DN) through the detection of the methylation level of MMP-9 gene promoter region in the peripheral blood of patients with DN in different periods and serum MMP-9 concentration. Methods: The methylation level of the MMP-9 gene promoter region was detected by methylation-specific polymerase chain reaction (MSP), and the content of MMP-9 in serum was determined by enzyme-linked immunosorbent assay (ELISA). Results: Results of the statistical analysis revealed that serum MMP-9 protein expression levels gradually increased in patients in the simple diabetic group, early diabetic nephropathy group and clinical diabetic nephropathy group, compared with the control group; and the difference was statistically significant (P < 0.05). Compared with the control group, the methylation levels of MMP-9 gene promoter regions gradually decreased in patients in the simple diabetic group, early diabetic nephropathy group, and clinical diabetic nephropathy group; and the difference was statistically significant (P < 0.05). Furthermore, correlation analysis results indicated that the demethylation levels of the MMP-9 gene promoter region was positively correlated with serum protein levels, urinary albumin to creatinine ratio (UACR), urea and creatinine; and was negatively correlated with GFR. Conclusion: The demethylation of the MMP-9 gene promoter region may be involved in the occurrence and development of diabetic nephropathy by regulating the expression of MMP-9 protein in serum.

Abstract

Objective: This study aims to explore the relationship between the methylation of matrix metalloproteinase (MMP)-9 gene promoter region and diabetic nephropathy (DN) through the detection of the methylation level of MMP-9 gene promoter region in the peripheral blood of patients with DN in different periods and serum MMP-9 concentration. Methods: The methylation level of the MMP-9 gene promoter region was detected by methylation-specific polymerase chain reaction (MSP), and the content of MMP-9 in serum was determined by enzyme-linked immunosorbent assay (ELISA). Results: Results of the statistical analysis revealed that serum MMP-9 protein expression levels gradually increased in patients in the simple diabetic group, early diabetic nephropathy group and clinical diabetic nephropathy group, compared with the control group; and the difference was statistically significant (P < 0.05). Compared with the control group, the methylation levels of MMP-9 gene promoter regions gradually decreased in patients in the simple diabetic group, early diabetic nephropathy group, and clinical diabetic nephropathy group; and the difference was statistically significant (P < 0.05). Furthermore, correlation analysis results indicated that the demethylation levels of the MMP-9 gene promoter region was positively correlated with serum protein levels, urinary albumin to creatinine ratio (UACR), urea and creatinine; and was negatively correlated with GFR. Conclusion: The demethylation of the MMP-9 gene promoter region may be involved in the occurrence and development of diabetic nephropathy by regulating the expression of MMP-9 protein in serum.
Get Citation

Keywords

diabetic nephropathy, matrix metalloproteinase-9, DNAmethylation

About this article
Title

Study on the relationship between the methylation of the MMP-9 gene promoter region and diabetic nephropathy

Journal

Endokrynologia Polska

Issue

Vol 69, No 3 (2018)

Pages

269-275

Published online

2018-05-08

DOI

10.5603/EP.a2018.0029

Pubmed

29952417

Bibliographic record

Endokrynologia Polska 2018;69(3):269-275.

Keywords

diabetic nephropathy
matrix metalloproteinase-9
DNAmethylation

Authors

Xiao-Hui Yang
Shi-Ya Feng
Yang Yu
Zhou Liang

References (15)
  1. Wu KI, Schmid-Schönbein GW. Nuclear factor kappa B and matrix metalloproteinase induced receptor cleavage in the spontaneously hypertensive rat. Hypertension. 2011; 57(2): 261–268.
  2. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 2008; 75(2): 346–359.
  3. Chicoine E, Estève PO, Robledo O, et al. Evidence for the role of promoter methylation in the regulation of MMP-9 gene expression. Biochem Biophys Res Commun. 2002; 297(4): 765–772.
  4. Roach HI, Yamada N, Cheung KSC, et al. Association between the abnormal expression of matrix-degrading enzymes by human osteoarthritic chondrocytes and demethylation of specific CpG sites in the promoter regions. Arthritis Rheum. 2005; 52(10): 3110–3124.
  5. Betz B, Conway BR. Recent advances in animal models of diabetic nephropathy. Nephron Exp Nephrol. 2014; 126(4): 191–195.
  6. Wren JD, Garner HR. Data-mining analysis suggests an epigenetic pathogenesis for type 2 diabetes. J Biomed Biotechnol. 2005; 2005(2): 104–112.
  7. Keating ST, El-Osta A. Epigenetic changes in diabetes. Clin Genet. 2013; 84(1): 1–10.
  8. Sidaway P. Diabetes: Epigenetic changes lead to impaired wound healing in patients with T2DM. Nat Rev Endocrinol. 2015; 11(2): 65.
  9. Sapienza C, Lee J, Powell J, et al. DNA methylation profiling identifies epigenetic differences between diabetes patients with ESRD and diabetes patients without nephropathy. Epigenetics. 2011; 6(1): 20–28.
  10. McLennan SV, Kelly DJ, Cox AJ, et al. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia. 2002; 45(2): 268–275.
  11. Tashiro K, Koyanagi I, Ohara I, et al. Levels of urinary matrix metalloproteinase-9 (MMP-9) and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal. 2004; 18(3): 206–210.
  12. Li SY, Huang PH, Yang AH, et al. Matrix metalloproteinase-9 deficiency attenuates diabetic nephropathy by modulation of podocyte functions and dedifferentiation. Kidney Int. 2014; 86(2): 358–369.
  13. Campos K, Gomes CC, Farias LC, et al. DNA Methylation of MMP9 Is Associated with High Levels of MMP-9 Messenger RNA in Periapical Inflammatory Lesions. J Endod. 2016; 42(1): 127–130.
  14. Sato N, Maehara N, Su GH, et al. Effects of 5-aza-2'-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J Natl Cancer Inst. 2003; 95(4): 327–330.
  15. Chicoine E, Estève PO, Robledo O, et al. Evidence for the role of promoter methylation in the regulation of MMP-9 gene expression. Biochem Biophys Res Commun. 2002; 297(4): 765–772.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl